Afferent Arteriolar Vasodilation to the Sulfonimide Analog of 11,12-Epoxyeicosatrienoic Acid Involves Protein Kinase A
poxyeicosatrienoic acids (EET) produced by the kidney affect both renal blood flow 1, 2, 3, 4 and tubular transport function. 5, 6 In this regard, renal enzymatic epoxygenase activity increases in some strains of rats on a high-salt diet 7, 8 and has been shown to be altered during the development of hypertension. 9, 10 Thus, renal epoxygenase metabolites have been implicated in the maintenance of water and electrolyte balance.
More recently, EETs have been demonstrated to mediate agonist-induced endothelium-dependent vasodilation 11, 12 and have been considered an endothelium-derived hyperpolarizing factor (EDHF). 13 In the renal circulation, EDHF appears to mediate a large portion of the vasodilatory response to bradykinin 11 and an endothelial-derived cytochrome P450 metabolite of arachidonic acid has been implicated as an EDHF. [12] [13] [14] We previously demonstrated that 11,12-EET and 14,15-EET vasodilate interlobular arteries and afferent arterioles. 4 Additionally, the major epoxide produced by the rat kidney, 11,12(R, S)-EET, vasodilated the interlobular arteries and afferent arterioles, whereas, 11,12(S, R)-EET did not affect microvascular tone. 4 Vasodilation to 11,12-EET resulted from a direct action of the epoxide on preglomerular vascular smooth muscle 4 and 11,12-EET has also been shown to dilate renal arteries and activate Ca 2ϩ -activated K ϩ channels (K Ca ). 15 These actions of 11,12-EET on renal vessels and K Ca channels are consistent with the possibility that 11,12-EET is an EDHF.
Vasodilation and activation of vascular smooth muscle K ϩ channels can occur via stimulation of cAMP-dependent and cGMP-dependent protein kinases. 16 Therefore, the present study determined the contribution of cAMP-and cGMPdependent protein kinases in mediating the 11,12-EET effect on afferent arteriolar diameter. Experiments were performed with the newly synthesized N-methylsulfonimide analog of 11,12-EET which is designed to resist esterification and ␤-oxidation while retaining full biological activity. 17 Preglomerular vascular responses to the 11,12-EET analog and the involvement of protein kinases were determined utilizing the in vitro perfused juxtamedullary nephron preparation.
Methods

Vascular Preparation
Experiments were performed on male Sprague-Dawley rats (Charles River Laboratories, Wilmington, Mass) weighing an average of 367Ϯ9 g. All experiments were approved by the Tulane University Animal Care and Use Committee. The rats were anesthetized with sodium pentobarbital (40 mg/kg body wt IP), the right carotid artery was cannulated and a midline abdominal incision was made. The right renal artery of the kidney was cannulated via the superior mesenteric artery and the kidney was immediately perfused with a Tyrode's solution containing 6% albumin and a mixture of L-amino acids. 18 Blood was collected through the carotid artery cannula into a heparinized syringe (2000 U). Erythrocytes were separated from plasma and leukocytes by centrifugation, as previously described. 18 The erythrocytes were resuspended in Tyrode's solution containing 6% albumin to yield a hematocrit of 20%. The reconstituted blood solution was filtered and stirred continuously in a closed reservoir that was pressurized by a 95% O 2 -5% CO 2 tank. The kidney was removed and maintained in an organ chamber at room temperature throughout the isolation and dissection procedure. The juxtamedullary microvasculature was isolated for study as previously described. 18 The Tyrode's solution was then replaced by reconstituted blood and renal artery perfusion pressure measured, at the tip of the cannula, was set to 100 mm Hg. The organ chamber was warmed and the tissue surface was continuously superfused with a Tyrode's solution containing 1% albumin at 37°C. After a 20-minute equilibration period, an afferent arteriole was chosen for study and baseline diameter measured.
Afferent arteriolar diameters were measured using videomicroscopy techniques. The tissue was transilluminated on the fixed stage of a Leitz Laborlux microscope equipped with a 75-W xenon lamp and a ϫ40 water-immersion objective. Video images of the tissue under study were generated by a Newvicon camera, passed through a time-date generator, displayed on a monitor, and videotaped for later analysis. Vessel diameter was measured using a calibrated image-shearing monitor, which yielded reproducible measurements within 0.5 m.
Synthesis of the N-Methylsulfonimide Analog of 11,12-EET (Ϯ)-11,12-EET was prepared as previously described. 19 (Ϯ)-11,12-EET (18 mg, 0.05 mmol) and N-hydroxysuccinimide (7.1 mg, 0.06 mmol) were azeotropically dried with benzene (3ϫ20 mL), then dissolved in dry tetrahydrofuran (1 mL) and cooled to 0°C. To this was added dicyclohexylcarbodimide (12.5 mg, 0.06 mmol) and the solution vigorously stirred. After 12 hours at room temperature, the solvent was removed in vacuo and the crude product purified by SiO 2 column chromatography using EtOAc/hexane (30:70) , to give the corresponding N-hydroxysuccinimide ester as a gum (21 mg The above active ester (21 mg, 0.05 mmol), methanesulfonimide (47.6 mg, 0.5 mmol), and 4-dimethylaminopyridine (6.1 mg, 0.05 mmol) were dried in vacuo (0.1 mm Hg) for 2 hours, mixed with anhydrous hexamethylphosphoramide (0.05 mL), and heated at 90°C under an argon atmosphere. After 1.5 hours, the reaction mixture was cooled and partitioned between water and EtOAc. The aqueous layer was extracted twice more with EtOAc. The combined organic extracts were dried over MgSO 4 , evaporated in vacuo, and the residue purified via preparative TLC using EtOAc/hexane (1:1) to afford the N-methylsulfonimide analog of (Ϯ)-11,12-EET (11. 
Afferent Arteriolar Vasodilation to the 11,12-EET Analog and the Involvement of Protein Kinases
Stock solutions of the N-methylsulfonimide analog of 11,12-EET in ethanol were kept in sealed vials and stored under nitrogen at Ϫ80°C until the experiment. Immediately before use, the stock solution of the 11,12-EET analog was added to the superfusion solution. The final concentration of the ethanol vehicle was Ͻ0.05% (vol/vol). The diameter response to the 11,12-EET analog was maximal by 1 to 2 minutes and sustained over a 15-minute period. All subsequent experiments monitored the vascular diameter over a 5-minute period.
An afferent arteriole was chosen for experiments designed to determine the involvement of protein kinases in the vasodilation to the sulfonimide analog of 11,12-EET. Measurements of afferent arteriolar diameters were made at least 50 m from any branch points. Vessels were preconstricted with a submaximal concentration of norepinephrine (0.5 mol/L; Sanofi/Winthrop Pharm). Administration of norepinephrine to the blood perfusate decreased the diameter of afferent arterioles from 22Ϯ1 to 18Ϯ1 m (nϭ41). After preconstriction with norepinephrine, the afferent arteriolar response to increasing concentrations of the N-methylsulfonimide analog of 11,12-EET (0.01 to 100 nmol/L) was determined. After the control dose response to the 11,12-EET analog was obtained, the protein kinase inhibitors were added to the perfusate and superfusate for 20 minutes to ensure complete blockade. The afferent arteriolar dose response to the 11,12-EET analog was repeated in the presence of protein kinase A (PKA) inhibition with H-89 20 (10 mol/L; Biomol) or myristolated PKI(14 -22) amide 21 (5 mol/L; Biomol). The response of the afferent arterioles to the 11,12-EET analog was also determined before and after inhibition of protein kinase G (PKG) with histone H2B (29 -35) 22 Additional experiments were performed to determine the effectiveness of the protein kinase inhibitors for blocking protein kinase activity. The ability of H-89 or myristolated PKI to inhibit the afferent arteriolar vasodilatory response to the cell permeable cAMP analog, 8-bromo-cAMP was determined. After the afferent arteriolar response to 8-bromo-cAMP (1 nmol/L to 100 mol/L; Biomol) was determined, the PKA inhibitor H-89 or myristolated PKI was administered to the perfusate and superfusate and the response to 8-bromo-cAMP redetermined. Likewise, the ability of the PKG inhibitor histone H2B to inhibit the afferent arteriolar vasodilatory response to the cell permeable cGMP analog, 8-bromo-cGMP (1 nmol/L to 100 mol/L; Biomol) was determined.
Statistics
Data are presented as meanϮSEM. Significance of differences in mean values for the dose-response effect was evaluated by analysis of variance for repeated measures followed by Duncan's multiple range test. A value of PϽ0.05 was considered statistically significant.
Results
Effect of PKA Inhibitors on the Afferent Arteriolar Response to the 11,12-EET Analog
Initial studies were performed comparing the vascular activity of 11,12-EET and the N-methylsulfonimide analog of 11,12-EET on afferent arteriolar diameter. Both 11,12-EET and the sulfonimide analog of 11,12-EET elicited similar vasodilatory responses. Afferent arteriolar diameter averaged 18Ϯ2 m (nϭ3) and increased by 11Ϯ2% and 15Ϯ3% in response to 10 and 100 nmol/L of the 11,12-EET analog. Likewise, afferent arteriolar diameter increased by 12Ϯ3% and 17Ϯ4% in response to 10 and 100 nmol/L 11,12-EET. Figure 1 depicts the effect of the PKA inhibitor, H-89, on the afferent arteriolar vasodilatory response to the 11,12-EET analog. Afferent arteriolar diameter increased after superfusion with the 11,12-EET analog and reached a steady state within 2 minutes. In the presence of the PKA inhibitor H-89, the afferent arteriolar vasodilation in response to the sulfonimide analog of 11,12-EET was significantly attenuated. The effect of PKA inhibition on the steady state responses to the 11,12-EET analog is presented in Figure 2 . The vasodilatory response to 100 nmol/L of the 11,12-EET analog averaged 13Ϯ2% and was greatly attenuated in the presence of H-89 and averaged 5Ϯ2%. Likewise, the increase in the afferent arteriolar diameter to 100 nmol/L of the 11,12-EET analog averaged 15Ϯ4% and was significantly attenuated by the PKA inhibitor, myristolated PKI. In the presence of myristolated PKI, 100 nmol/L of the 11,12-EET analog increased the afferent arteriolar diameter by only 2Ϯ1%.
To control for the possibility that PKA inhibition might nonspecifically interfere with microvascular vasodilatory responses, we confirmed the ability of these arterioles to vasodilate in response to acetylcholine. Acetylcholine (1 mol/L), administered at the end of the experiment, increased afferent arteriolar diameter by 17Ϯ2% (nϭ2) and 21Ϯ5% (nϭ2) in the presence of H-89 and myristolated PKI, respectively. Figure 3 presents the effect of the PKG inhibitor (left panel) and the guanylyl cyclase inhibitor, ODQ (right panel), on the afferent arteriolar response to N-methylsulfonimide analog of 11,12-EET. Afferent arteriolar diameter averaged 19Ϯ1 m (nϭ12) and increased by 15Ϯ1% in response to superfusion of 100 nmol/L of the 11,12-EET analog. The PKG inhibitor, histone H2B, did not significantly alter the vasodilation and afferent arteriolar diameter increased by 15Ϯ3% in response to 100 nmol/L of the 11,12-EET analog during PKG inhibition. The afferent arteriolar response to the sulfonimide analog of 11,12-EET was not altered by the guanylyl cyclase inhibitor ODQ. In the presence of ODQ, afferent arteriolar diameter increased by 12Ϯ2% in response to 100 nmol/L of the 11,12-EET analog.
Effect of PKG and Guanylyl Cyclase Inhibition on the Afferent Arteriolar Response to the 11,12-EET Analog
Effect of Protein Kinase Inhibitors on the Afferent Arteriolar Vasodilation Response to 8-Bromo Analogs
The effect of the PKA inhibitors, H-89 and myristolated PKI, on the afferent arteriolar vasodilation to 8-bromo-cAMP is depicted in the top panel of Figure 4 . 8-Bromo-cAMP dose-dependently increased afferent arteriolar diameter. The afferent arteriolar vasodilatory response to 8-bromo-cAMP was significantly attenuated in the presence of PKA inhibition. 8-bromo-cAMP (100 mol/L) increased afferent arteriolar diameter by 11Ϯ3% before the addition of PKA inhibitors and decreased diameter by 2Ϯ2% and 1Ϯ1% in the presence of H-89 and myristolated PKI, respectively.
Experiments were also performed to determine the ability of histone H2B to inhibit the afferent arteriolar vasodilation to 8-bromo-cGMP. Afferent arteriolar diameter increased dose dependently in response to 8-bromo-cGMP (Figure 4 , bottom panel). The afferent arteriolar diameter response to 10 and 100 mol/L 8-bromo-cGMP was 9Ϯ2% and 10Ϯ3%, respectively, under control conditions. In contrast, in the presence of histone H2B, these responses were attenuated to 2Ϯ2% and 1Ϯ1%, respectively. 
Discussion
The present study determined the contribution of cAMP-and cGMP-dependent protein kinase pathways to the afferent arteriolar vasodilation elicited by the N-methylsulfonimide analog of 11,12-EET. We directly examined the response of the newly synthesized N-methylsulfonimide analog of 11,12-EET on the afferent arteriole using the in vitro blood-perfused juxtamedullary nephron preparation. The 11,12-EET analog, which is designed to resist esterification and ␤-oxidation, had very similar biological properties compared with 11,12-EET. In cultured renal epithelial cells, the sulfonimide analogs of 11,12-EET and 14,15-EET have the same mitogenic activity and utilize the same cellular signaling pathways as their endogenous counterparts. 25 Likewise, the addition of the N-sulfonimide to cP450 inhibitors did not change the potency or selectivity of their inhibitory activity. 26 In the present study, the afferent arteriolar diameter increased dosedependently in response to superfusion of the 11,12-EET analog and this response paralleled the vasodilation observed with the native 11,12-EET. Inhibition of PKA significantly attenuated the 11,12-EET analog-mediated vasodilation of the afferent arteriole, whereas inhibition of PKG or guanylyl cyclase did not alter the response. These data suggest that the increase in afferent arteriolar diameter elicited by the 11,12-EET analog involves activation of the cAMP-dependent protein kinase pathway.
EETs are synthesized by endothelial cells, activate vascular smooth muscle K ϩ channels, hyperpolarize vascular smooth cells, and vasodilate blood vessels. 27 Thus, EETs have been considered an EDHF. 12, 13, 14 The major epoxygenase metabolites of arachidonic acid produced in the kidney are 11,12-EET and 14,15-EET. 28, 29 Renal microvessels and microsomes prepared from these vessels metabolize arachidonic acid to 11,12-EET and 14,15-EET and their corresponding diols. 30, 31 Recently, it has been suggested that 11,12-EET is the EDHF that mediates a large proportion of the bradykinin-induced vasodilation in coronary and renal arteries. 11,12 11,12-EET elicits endothelium-and cyclooxygenase-independent vasodilation of the preglomerular vasculature, whereas the epoxide hydrolase metabolite 11,12-dihydroxyeicosatrienoic acid did not significantly affect afferent arteriolar tone. 4 The vasodilation of larger caliber renal arteries by 11,12-EET was significantly attenuated by K ϩ channel inhibitors. 15 Likewise, 11,12-EET increased the outward K ϩ current of the large conductance K Ca channel active in renal arterial vascular smooth muscle cells. 15 In these experiments, the large conductance K Ca channel activity was unaltered in renal arterial vascular smooth muscle cells exposed to 11,12-EET on the cytoplasmic or external face of excised membrane patches. This suggests that cytoplasmic signal transduction factors are required for activation of K ϩ channels by 11,12-EET. The results of the present study demonstrate that vasodilation of afferent arterioles by the sulfonimide analog of 11,12-EET requires activation of the cAMP-dependent protein kinase pathway and suggest that PKA participates as a cellular signaling factor for 11,12-EET to activate K ϩ channels. The ability of 11,12-EET to relax vascular smooth muscle and control organ blood flow is not limited to the renal vasculature. However, the ability of EETs to vasodilate does appear to depend on the vasculature from which the vessels are isolated. EETs do not affect cell membrane potential or cause relaxation of internal carotid arteries isolated from guinea pig, 32 whereas coronary and cerebral arteries generate epoxygenase metabolites and, like the renal vasculature, 11,12-EET causes vasodilation. 13, 33 The vasodilatory action of 11,12-EET on the cat cerebral vasculature is associated with activation of vascular smooth muscle cell K Ca channels. 33 In contrast, the 11,12-EET-induced vasodilation of the newborn pig cerebral circulation requires an intact prostanoid system and prostacyclin receptor activation. 34 In freshly isolated coronary artery smooth muscle cells, 11,12-EET causes membrane hyperpolarization and appears to be selective for the K Ca channel since the delayed rectifier K ϩ (K drf ) channels were unaffected by 11,12-EET. 35 Interestingly, the prostaglandin I 2 analog iloprost increases the activity of the K drf channels without affecting the K Ca channels in the coronary vasculature. 35 Activation of the coronary artery K Ca channels by 11,12-EET appears to be due to activation of a GTP binding protein, G s and depends on cytoplasmic signaling factors. 36 Although G s can activate adenylyl cyclase and cause PKA-dependent phosphorylation of the K Ca channel, 16 bovine coronary artery cAMP levels were not significantly affected by incubation with 11,12-EET. 13 This finding is not consistent with the observation of the present study that the 11,12-EET analog-mediated vasodilation of the afferent arteriole is greatly attenuated by 2 chemically distinct inhibitors of PKA. One possible explanation for this discrepancy could be that the sensitivity of the cAMP assay was not sufficient to allow for detection of physiologically significant increases in activity. 11,12-EET activation of the cAMP-dependent pathway has been observed in heart cells. 37 Ventricular myocytes incubated with 11,12-EET did significantly elevate intracellular cAMP levels and in this cell type 11,12-EET may act to modulate L-type Ca 2ϩ channel current. 37 Another possibility is that the vascular tissue cAMP measurements have been done on larger caliber vessels that appear to be less sensitive to the vasorelaxant effects of EETs 13 and therefore may not utilize the cAMP pathway to the same extent as smaller caliber vessels. Further studies are required to clearly delineate the cellular-signaling steps responsible for the afferent arteriolar vasodilation in response to 11,12-EET.
Recent studies have shown that PKG can be the mediator of not only cGMP-dependent but also cAMP-dependent vasodilators. 38 The present results demonstrate that inhibition of PKG or guanylyl cyclase did not affect the afferent arteriolar vasodilation to the sulfonimide analog of 11,12-EET. This finding is supported by a number of previous studies which have demonstrated that the cGMP-dependent protein kinase pathway is not involved in the vasodilation produced by endothelial epoxygenase metabolites. In the rat kidney, arachidonic acid is metabolized by the endothelium to a cP450 vasodilatory product and this vasorelaxation was not influenced by guanylyl cyclase inhibition. 39 Likewise, epoxygenase metabolites, when incubated with bovine coronary arteries, significantly decreased tissue cGMP content. 13 In addition, brefeldin A inhibited the EDHF-mediated vasorelaxation and production of EDHF elicited by bradykinin in porcine coronary arteries but did not affect the accumulation of cGMP. 40 Thus, the results of the current study and those of previous studies do not support a role for the cGMPdependent protein kinase pathway in the vasodilatory response to 11,12-EET.
In summary, the N-methylsulfonimide analog of 11,12-EET vasodilated afferent arterioles of juxtamedullary nephrons. The afferent arteriolar vasodilation elicited by the 11,12-EET analog was significantly attenuated by inhibitors of PKA but was unaltered by inhibition of PKG or guanylyl cyclase. These results demonstrate that activation of PKA is an important intracellular-signaling mechanism responsible for the afferent arteriolar vasodilation elicited by the sulfonimide analog of 11,12-EET.
